The road over the pandemic bridge to the new normal city – with Baxter

by Paid content

03 July 2020


Over the last few months we have experienced something that is unrivalled in living memory – a global pandemic. COVID-19 has hit healthcare systems like a tornado, lifting up areas and placing them elsewhere, causing a whirlwind of activity not seen in recent times.

Baxter logoDuring this period, developing treatment pathways that minimise social interaction and reassure patients will be critical to success. Protocols should be challenged to maximise the use of treatments that can be administered outside of the acute hospital setting or in the home. And this should include early discharge, even if treatments need to continue in the community. 

Optimising pathways in this way will not only help throughput, but will protect scarce resources. As part of the phase 2 response to COVID-19, NHS England expects changes in the areas where organisations are incurring necessary and additional COVID-19 expenditure, including remote management of patients, support for stay at home models and hospital discharge programmes.

Baxter has been there to take every reasonable step possible to support our hospitals and healthcare partners during the current COVID pandemic. We are working collaboratively on shared learnings, and steps we can take in partnership, to prepare for a range of future scenarios. 

Here are just some examples of the support we continue to provide:

Remote monitoring of patients
Baxter’s cloud-based communication platform that connects home dialysis devices to renal units enables clinicians to manage their patients remotely.
 
Stay at home models
During the COVID period, Baxter’s collaboration with the NHS has enabled the number of prevalent peritoneal dialysis patients at home to increase by 5%. This means patients are able to receive their treatment and products at home.
Baxter has also increased capacity for patient training enabling more
patients to access this model of care.
 
Early discharge
Optimising a patient for day case surgery prevents the need for admission and releases capacity, creating a bed that could support the treatment of the next surgical patient.

Also, using advanced surgical techniques can reduce the need for blood transfusions so reducing the chances of needing an intensive care unit bed. 
 
Enabling patients to go home and self-administer intravenous antibiotics frees-up a bed that could support another patient in need. During the height of the COVID peak, the use of self-administered antibiotics, delivered with elastomeric pumps, supported the NHS in its aim to free up over 30,000 beds1.
 
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we have operated at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen
 
Baxter’s Evolving Heath Programme partners with the NHS to deliver the outcomes that matter, maximizing value across the patient pathway. 
 
If you would like to find out more about our Evolving Health Programme and how Baxter can work with you in your local health economy, please give our Evolving Health team a call on 01635 206000.

1Next steps on the NHS response to Covid-19 letter 17 March 2020 page 2. Author Simon Stevens.

UKI/MG234/20-0003 June 2020